Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 114583516 | 11458351 | 6 | F | 20140521 | 20160908 | 20150904 | 20160914 | EXP | PHHY2014CA064712 | NOVARTIS | 72.67 | YR | F | Y | 0.00000 | 20160914 | MD | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 114583516 | 11458351 | 1 | PS | SANDOSTATIN | OCTREOTIDE ACETATE | 1 | Subcutaneous | UNK, BID | Y | 19667 | BID | ||||||||
| 114583516 | 11458351 | 2 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 10 MG, QMO | 29.3065186 | MG | U | 0 | 10 | MG | /month | ||||
| 114583516 | 11458351 | 3 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 20 MG, QMO | 29.3065186 | MG | U | 0 | 20 | MG | /month | ||||
| 114583516 | 11458351 | 4 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 20 MG, EVERY 3 WEEKS | 29.3065186 | MG | U | 0 | 20 | MG | |||||
| 114583516 | 11458351 | 5 | C | CORTISONE | CORTISONEHYDROCORTISONE | 1 | Unknown | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 114583516 | 11458351 | 1 | Neuroendocrine tumour |
| 114583516 | 11458351 | 2 | Neuroendocrine tumour |
| 114583516 | 11458351 | 5 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 114583516 | 11458351 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 114583516 | 11458351 | Abdominal pain | |
| 114583516 | 11458351 | Abdominal tenderness | |
| 114583516 | 11458351 | Blood pressure increased | |
| 114583516 | 11458351 | Blood pressure systolic increased | |
| 114583516 | 11458351 | Dizziness | |
| 114583516 | 11458351 | Drug ineffective | |
| 114583516 | 11458351 | Headache | |
| 114583516 | 11458351 | Heart rate decreased | |
| 114583516 | 11458351 | Inappropriate schedule of drug administration | |
| 114583516 | 11458351 | Injection site mass | |
| 114583516 | 11458351 | Injection site pain | |
| 114583516 | 11458351 | Lymphoma | |
| 114583516 | 11458351 | Malaise | |
| 114583516 | 11458351 | Malignant neoplasm progression | |
| 114583516 | 11458351 | Nausea | |
| 114583516 | 11458351 | Neoplasm progression | |
| 114583516 | 11458351 | Oedema peripheral | |
| 114583516 | 11458351 | Peripheral swelling | |
| 114583516 | 11458351 | Second primary malignancy | |
| 114583516 | 11458351 | Wound | |
| 114583516 | 11458351 | Wound complication |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 114583516 | 11458351 | 1 | 20140517 | 20140526 | 0 | |
| 114583516 | 11458351 | 2 | 20140529 | 20140626 | 0 | |
| 114583516 | 11458351 | 3 | 20140724 | 20160713 | 0 | |
| 114583516 | 11458351 | 4 | 20160805 | 0 |